A randomized, crossover, open study in order to compare treatment satisfaction with insulin
Glargine plus insulin Apidra Vs NPH insulin plus insulin Apidra in newly diagnosed children
and adolescents with type 1 diabetes.
The study will include two consecutive periods: 2 weeks run in period and 24 weeks
intervention period, divided into two separate treatment periods of 12 weeks. According to
randomization, each patient will be treated consecutively with both treatment arms: 12 weeks
with insulin Glargine and than 12 weeks with NPH insulin or 12 weeks with insulin NPH ad than
12 weeks with insulin Glargine. Patients will complete DTSQ (Diabetes Treatment Satisfaction
Questionnaire) at months 0, 12 and 24 weeks, before and at the end of each study arm.